Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugs.

Autor: Ramirez G, Klotz J, Strawitz JG, Wilson WL, Cornell GN, Madden RE, Minton JP
Jazyk: angličtina
Zdroj: Oncology [Oncology] 1975; Vol. 32 (3-4), pp. 101-8.
DOI: 10.1159/000225056
Abstrakt: A randomized clinical trial, involving approximately 100 patients, that compared two combination therapy regimens (5 FU, methotrexate, vincristine, cyclophosphamide with and without prednisone) in advanced breast cancer showed a significantly higher rate of response for the 5-drug therapy group (62.5 versus 44.2%). However, no significant difference in survival has been observed to date. Some differences in toxicity were observed, e.g. a significantly greater number of cases with mild diarrhea for the 5-drug regimen, and a few more cases of sensory loss (not significant) and significantly more severe leukopenia (p value 0.06) for the 4-drug regimen.
Databáze: MEDLINE